MY192532A - Liquid pharmaceutical composition - Google Patents
Liquid pharmaceutical compositionInfo
- Publication number
- MY192532A MY192532A MYPI2019001479A MYPI2019001479A MY192532A MY 192532 A MY192532 A MY 192532A MY PI2019001479 A MYPI2019001479 A MY PI2019001479A MY PI2019001479 A MYPI2019001479 A MY PI2019001479A MY 192532 A MY192532 A MY 192532A
- Authority
- MY
- Malaysia
- Prior art keywords
- composition
- liquid pharmaceutical
- pharmaceutical composition
- relates
- package
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960003989 tocilizumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196625 | 2016-10-31 | ||
| PCT/EP2017/077793 WO2018078162A1 (en) | 2016-10-31 | 2017-10-30 | Liquid pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY192532A true MY192532A (en) | 2022-08-26 |
Family
ID=57218780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019001479A MY192532A (en) | 2016-10-31 | 2017-10-30 | Liquid pharmaceutical composition |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11291725B2 (enExample) |
| EP (2) | EP3532029B1 (enExample) |
| JP (2) | JP2019536761A (enExample) |
| KR (1) | KR20190078572A (enExample) |
| CN (1) | CN110062620B (enExample) |
| AU (1) | AU2017351805A1 (enExample) |
| BR (1) | BR112019006853B1 (enExample) |
| CA (1) | CA3040342A1 (enExample) |
| DK (1) | DK3532029T3 (enExample) |
| ES (1) | ES2882181T3 (enExample) |
| HU (1) | HUE054858T2 (enExample) |
| MY (1) | MY192532A (enExample) |
| RU (1) | RU2019116756A (enExample) |
| SG (1) | SG11201902531QA (enExample) |
| WO (1) | WO2018078162A1 (enExample) |
| ZA (1) | ZA201901736B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN110062620B (zh) * | 2016-10-31 | 2023-12-05 | 德国费森尤斯卡比有限公司 | 液体药物组合物 |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US12433948B2 (en) * | 2018-10-31 | 2025-10-07 | Richter Gedeon Nyrt | Aqueous pharmaceutical formulations |
| WO2021119330A1 (en) * | 2019-12-10 | 2021-06-17 | Maxim Skulachev | Polymer matrixes for different compositions of mitochondrially targeted antioxidants |
| EP4117727A2 (en) * | 2020-03-10 | 2023-01-18 | Tiziana Life Sciences PLC | Compositions of il-6/il-6r antibodies and methods of use thereof |
| ES2987347T3 (es) * | 2020-03-13 | 2024-11-14 | Lek Pharmaceuticals | Estabilización de composiciones farmacéuticas que comprenden polisorbato |
| WO2022006051A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Formulation of tocilizumab and method for treating covid-19 by inhalation |
| KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| US20230090654A1 (en) * | 2021-08-24 | 2023-03-23 | Homology Medicines, Inc. | Adeno-associated virus formulations |
| WO2024043837A1 (en) * | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
| KR102554775B1 (ko) | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| WO2024257040A1 (en) * | 2023-06-14 | 2024-12-19 | Enzene Biosciences Limited | Composition and stable liquid formulations comprising humanized anti-human interleukin 6 (il-6) receptor monoclonal antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW205553B (enExample) | 1991-04-25 | 1993-05-11 | Chugai Pharmaceutical Co Ltd | |
| DK1314437T3 (da) | 2000-08-11 | 2014-07-14 | Chugai Pharmaceutical Co Ltd | Stabiliserede antistofindeholdende præparater |
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| JP2009034095A (ja) * | 2007-07-06 | 2009-02-19 | Sanyo Chem Ind Ltd | タンパク質含有水溶液安定化剤、タンパク質含有水溶液の安定化方法及びタンパク質含有水溶液 |
| KR20100044261A (ko) * | 2007-08-27 | 2010-04-29 | 바이오제너릭스 에이지 | Ｇ-ｃｓｆ의 액상 조성물 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| KR20220070586A (ko) * | 2010-11-08 | 2022-05-31 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| US20150150979A1 (en) * | 2012-06-21 | 2015-06-04 | Ucb Pharma, S.A. | Pharmaceutical formulation |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
| CN110062620B (zh) * | 2016-10-31 | 2023-12-05 | 德国费森尤斯卡比有限公司 | 液体药物组合物 |
-
2017
- 2017-10-30 CN CN201780067178.XA patent/CN110062620B/zh active Active
- 2017-10-30 JP JP2019522329A patent/JP2019536761A/ja active Pending
- 2017-10-30 BR BR112019006853-8A patent/BR112019006853B1/pt active IP Right Grant
- 2017-10-30 MY MYPI2019001479A patent/MY192532A/en unknown
- 2017-10-30 KR KR1020197011677A patent/KR20190078572A/ko not_active Ceased
- 2017-10-30 US US16/346,215 patent/US11291725B2/en active Active
- 2017-10-30 WO PCT/EP2017/077793 patent/WO2018078162A1/en not_active Ceased
- 2017-10-30 RU RU2019116756A patent/RU2019116756A/ru unknown
- 2017-10-30 AU AU2017351805A patent/AU2017351805A1/en not_active Abandoned
- 2017-10-30 EP EP17797579.4A patent/EP3532029B1/en active Active
- 2017-10-30 EP EP21164822.5A patent/EP3964197A1/en active Pending
- 2017-10-30 CA CA3040342A patent/CA3040342A1/en active Pending
- 2017-10-30 ES ES17797579T patent/ES2882181T3/es active Active
- 2017-10-30 DK DK17797579.4T patent/DK3532029T3/da active
- 2017-10-30 SG SG11201902531QA patent/SG11201902531QA/en unknown
- 2017-10-30 HU HUE17797579A patent/HUE054858T2/hu unknown
-
2019
- 2019-03-20 ZA ZA201901736A patent/ZA201901736B/en unknown
-
2022
- 2022-02-24 US US17/680,155 patent/US20220175924A1/en active Pending
- 2022-07-22 JP JP2022117520A patent/JP7473603B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022166006A (ja) | 2022-11-01 |
| ES2882181T3 (es) | 2021-12-01 |
| DK3532029T3 (da) | 2021-06-07 |
| ZA201901736B (en) | 2020-11-25 |
| US20220175924A1 (en) | 2022-06-09 |
| EP3964197A1 (en) | 2022-03-09 |
| EP3532029B1 (en) | 2021-04-28 |
| WO2018078162A1 (en) | 2018-05-03 |
| RU2019116756A (ru) | 2020-11-30 |
| RU2019116756A3 (enExample) | 2021-02-26 |
| BR112019006853A2 (pt) | 2019-06-25 |
| CN110062620A (zh) | 2019-07-26 |
| EP3532029A1 (en) | 2019-09-04 |
| SG11201902531QA (en) | 2019-05-30 |
| JP2019536761A (ja) | 2019-12-19 |
| HUE054858T2 (hu) | 2021-10-28 |
| BR112019006853B1 (pt) | 2021-08-24 |
| US20190262450A1 (en) | 2019-08-29 |
| KR20190078572A (ko) | 2019-07-04 |
| JP7473603B2 (ja) | 2024-04-23 |
| US11291725B2 (en) | 2022-04-05 |
| CA3040342A1 (en) | 2018-05-03 |
| AU2017351805A1 (en) | 2019-04-11 |
| CN110062620B (zh) | 2023-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY192532A (en) | Liquid pharmaceutical composition | |
| PL3752510T3 (pl) | Makrocykle jako modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa, ich kompozycje farmaceutyczne, ich zastosowanie w leczeniu mukowiscydozy oraz proces ich wytwarzania | |
| BR112019005328A2 (pt) | composição farmacêutica líquida | |
| MX2017010400A (es) | Formulacion liquida estable para anticuerpos monoclonales. | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| EP4309643A3 (en) | Viscosity-reducing excipient compounds for protein formulations | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| WO2014176128A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| MY174991A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| HK1258276A1 (zh) | 用於治疗hiv的化合物和组合 | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| CA3010708A1 (en) | Methods of administering hepcidin | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| EP4406969A3 (en) | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| EP4477265A3 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| SG10201811078XA (en) | Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| WO2015156674A3 (en) | Method for treating cancer | |
| CR20190131A (es) | 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
| MX2016009464A (es) | Composiciones para el uso en el tratamiento de afecciones alergicas. | |
| EA201892157A1 (ru) | Фосфаплатиновые жидкие составы | |
| MX2021001361A (es) | Composicion liquida de fibrinogeno humano. |